Developing a method to improve T cell responses against solid tumors
Engineering synthetic feedback control in T cell signaling for anti-tumor immunity
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-10978167
This study is testing a new way to help special immune cells called T cells fight tough solid tumors better, so patients with these types of cancers might have more effective treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10978167 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of engineered T cells in fighting solid tumors, which have proven challenging compared to blood cancers. The approach involves creating a synthetic feedback control system that regulates T cell signaling, allowing these immune cells to maintain their anti-tumor functions without becoming exhausted from chronic stimulation by tumor cells. By carefully adjusting the intensity and duration of signaling, the goal is to improve T cell persistence and overall tumor control. Patients may benefit from this innovative strategy that aims to make T cell therapies more effective against solid tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who have not responded well to existing therapies.
Not a fit: Patients with blood cancers may not benefit from this research as it specifically targets solid tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with solid tumors, improving their chances of recovery.
How similar studies have performed: Other research has shown promise in enhancing T cell responses through similar signaling modulation techniques, indicating potential for success in this novel approach.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KUEH, HAO YUAN — UNIVERSITY OF WASHINGTON
- Study coordinator: KUEH, HAO YUAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.